Lineage Cell Therapeutics Maps COR1 Path With ‘Thaw and Inject' Cell Therapy Plan
Lineage Cell Therapeutics NYSEAMERICAN: LCTX used a conference call to outline its manufacturing strategy and development plans for COR1, a wholly owned preclinical cell transplant program being developed as a potential treatment for corneal endothelial disease.
Lineage: Don't Mistake A Cyclical Slump For A Broken Business
Lineage remains a Buy, offering a margin of safety and re-rating potential despite near-term macro and operational headwinds. Q1 saw AFFO per share decline 9.3% to $0.78, but guidance for Adj. EBITDA ($1.25–$1.3B) and AFFO per share ($2.75–$3.00) were maintained. LINE's cost reduction plan and automation investments target $110M annualized EBITDA improvement in 3–5 years, supporting long-term upside.
Lineage: Another Serious Fire Could Spell Trouble
Lineage Logistics faces significant operational and financial risks after two catastrophic fires at major cold storage facilities. Recent fires have led to lawsuits, public health concerns, and potential long-term brand damage, particularly in Los Angeles. Immediate costs include emergency relief and remediation, while longer-term impacts may include higher insurance premiums and increased operating expenses.
Lineage Cell Therapeutics Q1 Earnings Call Highlights
Lineage Cell Therapeutics NYSEAMERICAN: LCTX reported first-quarter 2026 results and used its earnings call to highlight progress across its cell therapy pipeline, including its lead OpRegen program in geographic atrophy, a newly launched corneal endothelial cell program called COR1, and ongoing manufacturing initiatives built around its AlloSCOPE platform.
Lineage, Inc. (LINE) Q1 2026 Earnings Call Transcript
Lineage, Inc. (LINE) Q1 2026 Earnings Call Transcript
Lineage, Inc. (LINE) Q1 FFO Beat Estimates
Lineage, Inc. (LINE) came out with quarterly funds from operations (FFO) of $0.78 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to FFO of $0.86 per share a year ago.
All You Need to Know About Lineage, Inc. (LINE) Rating Upgrade to Buy
Lineage, Inc. (LINE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Lineage: Cold Storage REIT Still Undervalued Thanks To Near-Term Headwinds
Lineage remains a buy, supported by strong fundamentals and a leading position in temperature-controlled warehouse REITs despite near-term macro headwinds. LINE delivered robust 2025 AFFO growth of 22.7% ($865M), but expects a ~14.7% per-share AFFO decline in 2026 amid weak occupancy and macro uncertainty. Dividend yield stands at 5.15% with a sustainable payout ratio, and management targets $110M run-rate cost savings over 3-5 years.
Lineage, Inc. (LINE) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Lineage, Inc. (LINE) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Lineage, Inc. (LINE) Beats Q4 FFO Estimates
Lineage, Inc. (LINE) came out with quarterly funds from operations (FFO) of $0.83 per share, beating the Zacks Consensus Estimate of $0.73 per share. This compares to FFO of $0.83 per share a year ago.
Lineage Vs. Americold: Why Tech Leadership Makes LINE The Superior REIT
Lineage (LINE) stands out as the cold storage industry leader, leveraging proprietary technology and geographic diversification to drive structural cost advantages over peers. LINE's LinOS platform is a significant competitive advantage, expected to boost margins and productivity, though rollout delays present near-term execution risk. Industry oversupply is being absorbed, with demand now outpacing new supply; LINE's 6% dividend yield is well covered and supported by a conservative payout ratio.
Lineage: Cold-Storage REIT Getting Too Hot To Ignore
Lineage is reiterated as a buy, trading at a significant discount to NAV and intrinsic value estimates, with strong recovery potential. LINE offers a ~6.1% dividend yield at a sustainable ~64% payout ratio, with plenty of room for increases or buybacks. Despite macro headwinds and lowered guidance, LINE continues to expand, leveraging its scale for future accretive growth and even industry consolidation.
